{'52WeekChange': 0.2014389,
 'SandP52WeekChange': 0.0644362,
 'address1': '343 Oyster Point Boulevard',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.01,
 'askSize': 2900,
 'averageDailyVolume10Day': 489837,
 'averageVolume': 741642,
 'averageVolume10days': 489837,
 'beta': 2.205042,
 'beta3Year': None,
 'bid': 5,
 'bidSize': 2900,
 'bookValue': 1.974,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.15,
 'dayLow': 4.96,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.423,
 'enterpriseToRevenue': None,
 'enterpriseValue': 225613104,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.278143,
 'fiftyTwoWeekHigh': 8.18,
 'fiftyTwoWeekLow': 2.45,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 62690874,
 'forwardEps': -1.27,
 'forwardPE': -3.9448822,
 'fromCurrency': None,
 'fullTimeEmployees': 90,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00642,
 'heldPercentInstitutions': 0.77154,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1411084800,
 'lastSplitFactor': '1:48',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/calithera.com',
 'longBusinessSummary': 'Calithera Biosciences, Inc., a clinical-stage '
                        'bio-pharmaceutical company, focuses on the discovery '
                        'and development of small molecule drugs directed '
                        'against tumor metabolism and tumor immunology targets '
                        'for the treatment of cancer in the United States. Its '
                        'lead product candidate is CB-839, an inhibitor of '
                        'glutaminase, which is in Phase II clinical trial to '
                        'treat solid tumors. The company also offers '
                        'INCB001158, an oral inhibitor of arginase that is in '
                        'Phase I/II clinical trial for the treatment of '
                        'hematology and oncology. The company is also '
                        'developing CB-280, an oral arginase inhibitor for the '
                        'treatment of cystic fibrosis; and CB-708, an orally '
                        'administered small molecule inhibitor of CD73. It has '
                        'a license agreement with Mars, Inc. to develop and '
                        "commercialize Symbioscience's portfolio of arginase "
                        'inhibitors for use in human healthcare. The company '
                        'also has clinical trial collaboration with '
                        'Bristol-Myers Squibb Company to evaluate nivolumab in '
                        'combination with CB-839. In addition, it has a '
                        'collaboration and license agreement with Incyte '
                        'Corporation for the research, development, and '
                        'commercialization of INCB001158, a small molecule '
                        'arginase inhibitor for the treatment of hematology '
                        'and oncology. Calithera Biosciences, Inc. was founded '
                        'in 2010 and is headquartered in South San Francisco, '
                        'California.',
 'longName': 'Calithera Biosciences, Inc.',
 'market': 'us_market',
 'marketCap': 352923968,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_109127589',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -90619000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.12,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.05,
 'phone': '650-870-1000',
 'previousClose': 5.16,
 'priceHint': 2,
 'priceToBook': 2.5379941,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.15,
 'regularMarketDayLow': 4.96,
 'regularMarketOpen': 5.12,
 'regularMarketPreviousClose': 5.16,
 'regularMarketPrice': 5.12,
 'regularMarketVolume': 472914,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 70443904,
 'sharesPercentSharesOut': 0.0398,
 'sharesShort': 2800273,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1477110,
 'shortName': 'Calithera Biosciences, Inc.',
 'shortPercentOfFloat': 0.0713,
 'shortRatio': 4.03,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CALA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.686,
 'twoHundredDayAverage': 5.8760433,
 'volume': 472914,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.calithera.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}